학술논문
ABX464 (obefazimod) for COVID-19 patients at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial
Document Type
Article
Author
Source
In Journal of Allergy and Clinical Immunology: Global April 2023
Subject
Language
ISSN
2772-8293